Bellevue Group AG Purchases 349,487 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Bellevue Group AG lifted its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 16.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,510,690 shares of the company's stock after acquiring an additional 349,487 shares during the period. Scholar Rock makes up 2.1% of Bellevue Group AG's portfolio, making the stock its 14th largest holding. Bellevue Group AG owned approximately 2.68% of Scholar Rock worth $108,512,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of Scholar Rock by 33.7% during the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock worth $589,316,000 after buying an additional 3,439,215 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Scholar Rock by 7.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock valued at $401,231,000 after acquiring an additional 629,315 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Scholar Rock by 17.6% in the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after buying an additional 708,817 shares during the period. Marshall Wace LLP boosted its position in shares of Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after purchasing an additional 2,732,546 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Scholar Rock during the 4th quarter worth about $86,043,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Scholar Rock

In other news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the transaction, the director now directly owns 30,319 shares in the company, valued at approximately $1,043,579.98. The trade was a 3.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Edward H. Myles sold 7,809 shares of Scholar Rock stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the transaction, the chief financial officer now directly owns 140,740 shares of the company's stock, valued at approximately $5,183,454.20. This trade represents a 5.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 255,231 shares of company stock valued at $9,220,236 in the last ninety days. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Stock Down 10.0 %

SRRK stock traded down $3.26 during trading hours on Tuesday, reaching $29.31. 1,998,408 shares of the stock were exchanged, compared to its average volume of 1,263,545. The company has a market cap of $2.78 billion, a price-to-earnings ratio of -12.47 and a beta of 0.37. The firm's 50-day moving average is $32.04 and its 200-day moving average is $35.84. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98.

Wall Street Analysts Forecast Growth

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.